Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 153.86 Million SEK | 25.23% |
| 2022 | 122.86 Million SEK | -22.8% |
| 2021 | 159.15 Million SEK | 12.26% |
| 2020 | 141.77 Million SEK | 97.88% |
| 2019 | 71.64 Million SEK | 23.75% |
| 2018 | 57.89 Million SEK | 43.21% |
| 2017 | 40.42 Million SEK | 25.73% |
| 2016 | 32.15 Million SEK | 14.38% |
| 2015 | 28.11 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 48.8 Million SEK | 9.55% |
| 2024 Q2 | 41.05 Million SEK | -15.87% |
| 2024 Q3 | 39.72 Million SEK | -3.25% |
| 2023 Q2 | 37.28 Million SEK | -1.3% |
| 2023 Q1 | 37.78 Million SEK | 5.52% |
| 2023 Q4 | 44.54 Million SEK | 30.04% |
| 2023 Q3 | 34.25 Million SEK | -8.13% |
| 2023 FY | 153.86 Million SEK | 25.23% |
| 2022 Q1 | 33.65 Million SEK | -27.42% |
| 2022 Q2 | 26.87 Million SEK | -20.16% |
| 2022 FY | 122.86 Million SEK | -22.8% |
| 2022 Q3 | 26.53 Million SEK | -1.24% |
| 2022 Q4 | 35.8 Million SEK | 34.92% |
| 2021 Q2 | 39.51 Million SEK | -12.2% |
| 2021 FY | 159.15 Million SEK | 12.26% |
| 2021 Q1 | 45 Million SEK | -2.17% |
| 2021 Q4 | 46.36 Million SEK | 63.97% |
| 2021 Q3 | 28.27 Million SEK | -28.43% |
| 2020 Q4 | 45.99 Million SEK | 114.62% |
| 2020 FY | 141.77 Million SEK | 97.88% |
| 2020 Q3 | 21.43 Million SEK | -47.09% |
| 2020 Q2 | 40.5 Million SEK | 19.74% |
| 2020 Q1 | 33.83 Million SEK | 68.68% |
| 2019 Q3 | 16.41 Million SEK | -5.43% |
| 2019 Q2 | 17.35 Million SEK | -2.55% |
| 2019 Q4 | 20.05 Million SEK | 22.17% |
| 2019 FY | 71.64 Million SEK | 23.75% |
| 2019 Q1 | 17.81 Million SEK | 16.87% |
| 2018 Q1 | 15.48 Million SEK | 43.45% |
| 2018 Q2 | 14.48 Million SEK | -6.47% |
| 2018 Q3 | 12.68 Million SEK | -12.45% |
| 2018 Q4 | 15.24 Million SEK | 20.19% |
| 2018 FY | 57.89 Million SEK | 43.21% |
| 2017 Q2 | 9.54 Million SEK | -3.47% |
| 2017 Q3 | 10.19 Million SEK | 6.73% |
| 2017 Q4 | 10.79 Million SEK | 5.93% |
| 2017 Q1 | 9.89 Million SEK | 11.5% |
| 2017 FY | 40.42 Million SEK | 25.73% |
| 2016 Q1 | 8.53 Million SEK | 0.0% |
| 2016 FY | 32.15 Million SEK | 14.38% |
| 2016 Q4 | 8.87 Million SEK | 16.7% |
| 2016 Q2 | 7.14 Million SEK | -16.35% |
| 2016 Q3 | 7.6 Million SEK | 6.44% |
| 2015 FY | 28.11 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -2365.422% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 88.793% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 88.793% |
| Arcoma AB | 163.01 Million SEK | 5.612% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 24.571% |
| BICO Group AB (publ) | 2.23 Billion SEK | 93.129% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 73.069% |
| CellaVision AB (publ) | 677.29 Million SEK | 77.282% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -1759.869% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -15660.524% |
| C-Rad AB (publ) | 424.61 Million SEK | 63.763% |
| Duearity AB (publ) | 1.65 Million SEK | -9202.721% |
| Dignitana AB (publ) | 86.06 Million SEK | -78.784% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -1393.854% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.517% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -2073.788% |
| Integrum AB (publ) | 104.11 Million SEK | -47.78% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -17902.478% |
| Mentice AB (publ) | 273.61 Million SEK | 43.764% |
| OssDsign AB (publ) | 112.15 Million SEK | -37.189% |
| Paxman AB (publ) | 210.11 Million SEK | 26.771% |
| Promimic AB (publ) | 37.07 Million SEK | -315.071% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -62960.246% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -561.936% |
| ScandiDos AB (publ) | 60.42 Million SEK | -154.624% |
| Sectra AB (publ) | 2.96 Billion SEK | 94.808% |
| Senzime AB (publ) | 35.75 Million SEK | -330.349% |
| SpectraCure AB (publ) | 318 Thousand SEK | -48285.849% |
| Stille AB | 294.89 Million SEK | 47.823% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 95.619% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 74.25% |